Takami Takeshi, Shigemasa Minori
Clinic Jinguumae, Kashihara, Japan.
Hypertens Res. 2003 Aug;26(8):609-14. doi: 10.1291/hypres.26.609.
When observed in elderly hypertensive patients, increased pulse pressure (PP) and arterial stiffness are known to be independent risk factors for cardiovascular diseases. Increased systolic blood pressure (SBP) leads to left ventricular hypertrophy, while decreased diastolic blood pressure (DBP) results in decreased coronary circulation. It is known that increased arterial stiffness is the major cause of increased PP. Thus basic morbid states of cardiac failure or ischemic heart diseases are more likely to develop in elderly hypertensive patients with increased PP and arterial stiffness, and there is need of antihypertensive drugs that decrease these effects in elderly hypertensives. In this study, we compared the effects of an angiotensin-receptor blocker (ARB: valsartan), an angiotensin-converting enzyme inhibitor (ACE-I: temocapril), and long-acting Ca antagonists (L- and N-type Ca channel blocker: cilnidipine; and L-type Ca channel blocker: nifedipine CR) on PP and arterial stiffness measured by pulse wave velocity in elderly hypertensive patients for 3 months. The ARB yielded the largest reductions in PP and brachial-ankle pulse wave velocity (baPWV), followed by the ACE-I and L- and N-type Ca channel blocker, while the L-type Ca channel blocker yielded no improvement. The effects on arterial stiffness and PP thus varied among the drug characteristics. Although ARB achieved the largest reduction in baPWV, this decrease was not associated with any reductions in PP, SBP, DBP, or mean blood pressure, as were the baPWV-decreases achieved by the other drugs, suggesting that ARB may further reduce the risk of arteriosclerosis in elderly hypertensive patients by decreasing arterial stiffness in addition to its antihypertensive effect.
在老年高血压患者中,脉压(PP)升高和动脉僵硬度增加是已知的心血管疾病独立危险因素。收缩压(SBP)升高会导致左心室肥厚,而舒张压(DBP)降低会导致冠状动脉循环减少。已知动脉僵硬度增加是PP升高的主要原因。因此,在PP升高和动脉僵硬度增加的老年高血压患者中,更易发生心力衰竭或缺血性心脏病等基础疾病,需要有能减轻这些影响的降压药物用于老年高血压患者。在本研究中,我们比较了血管紧张素受体阻滞剂(ARB:缬沙坦)、血管紧张素转换酶抑制剂(ACE-I:替莫卡普利)和长效钙拮抗剂(L型和N型钙通道阻滞剂:西尼地平;以及L型钙通道阻滞剂:硝苯地平控释片)对老年高血压患者3个月的PP和通过脉搏波速度测量的动脉僵硬度的影响。ARB使PP和臂踝脉搏波速度(baPWV)降低幅度最大,其次是ACE-I以及L型和N型钙通道阻滞剂,而L型钙通道阻滞剂未见改善。因此,这些药物对动脉僵硬度和PP的影响因药物特性而异。尽管ARB使baPWV降低幅度最大,但这种降低与PP、SBP、DBP或平均血压的降低均无关,而其他药物使baPWV降低时伴随着这些指标的降低,这表明ARB除降压作用外,可能通过降低动脉僵硬度进一步降低老年高血压患者的动脉硬化风险。